Syros Pharmaceuticals announced a peer-reviewed publication of results from its completed biomarker-directed Phase 2 trial of tamibarotene in combination with azacitidine in newly diagnosed patients with acute myeloid leukemia who are not eligible for standard intensive chemotherapy. These findings support Syros’ ongoing evaluation of tamibarotene for the treatment of AML and myelodysplastic syndrome patients with RARA overexpression. The paper, titled "Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARa Agonist, is a Novel Approach in AML," was published online in Blood Advances on December 7, 2022 at URL "We are excited to see a high CR rate and a rapid onset of response in newly diagnosed unfit AML patients with RARA overexpression treated with a combination of tamibarotene plus azacitidine. The biomarker test successfully identified AML patients positive for RARA overexpression who were enriched for response to tamibarotene and azacitidine relative to those patients who were negative for RARA overexpression. This observation further demonstrates that the activity of tamibarotene is dependent on the biology of RARA overexpression. In addition, the combination was generally well tolerated and provides the potential for a novel targeted treatment approach for patients with AML," said Stephane de Botton, M.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SYRS: